黄 震,郜启全,顾苏静,刘 慧,崔伯虎,任 薇.补肺活血胶囊联合盐酸氨溴索对慢性阻塞性肺疾病稳定期患者肺功能、睡眠质量及免疫功能的影响[J].,2022,(13):2555-2558 |
补肺活血胶囊联合盐酸氨溴索对慢性阻塞性肺疾病稳定期患者肺功能、睡眠质量及免疫功能的影响 |
Effects of Bufei Huoxue Capsule Combined with Ambroxol Hydrochloride on Pulmonary Function, Sleep Quality and Immune Function in Patients with Stable Chronic Obstructive Pulmonary Disease |
投稿时间:2022-01-06 修订日期:2022-01-28 |
DOI:10.13241/j.cnki.pmb.2022.13.030 |
中文关键词: 补肺活血胶囊 盐酸氨溴索 慢性阻塞性肺疾病 稳定期 肺功能 睡眠质量 免疫功能 |
英文关键词: Bufei Huoxue capsule Ambroxol hydrochloride Chronic obstructive pulmonary disease Stable Pulmonary function Sleep quality Immune function |
基金项目:安徽高校省级自然科学研究项目(KJ2013Z182) |
|
摘要点击次数: 721 |
全文下载次数: 413 |
中文摘要: |
摘要 目的:观察补肺活血胶囊联合盐酸氨溴索对慢性阻塞性肺疾病(COPD)稳定期患者肺功能、睡眠质量及免疫功能的影响。方法:选取2018年3月~2021年3月期间我院收治的COPD稳定期患者120例,按照计算机随机生成数据将患者分为对照组(给予盐酸氨溴索治疗,60例)和研究组(给予补肺活血胶囊联合盐酸氨溴索治疗,60例),两组均治疗3个月。观察两组疗效、肺功能、睡眠质量、免疫功能的变化,观察两组患者不良反应发生情况。结果:对比两组临床总有效率,研究组较对照组高(P<0.05)。治疗3个月后,研究组第一秒用力呼气容积(FEV1)、最大呼气流量(PEF)、用力肺活量(FVC)高于对照组(P<0.05)。治疗3个月后,研究组匹兹堡睡眠质量指数(PSQI)评分低于对照组(P<0.05)。治疗3个月后,研究组CD8+低于对照组,CD3+、CD4+、CD4+/CD8+高于对照组(P<0.05)。治疗3个月后,研究组症状体征积分低于对照组(P<0.05)。两组不良反应发生率对比无统计学差异(P>0.05)。结论:COPD稳定期患者采用盐酸氨溴索与补肺活血胶囊联合治疗可改善肺功能、免疫功能、睡眠质量,疗效可靠。 |
英文摘要: |
ABSTRACT Objective: To observe the effects of Bufei Huoxue capsule combined with ambroxol hydrochloride on pulmonary function, sleep quality and immune function in stable patients with chronic obstructive pulmonary disease(COPD). Methods: 120 patients with stable COPD who were treated in our hospital from March 2018 to March 2021 were collected. According to the computer randomly generated data, the patients were divided into control group (treated with ambroxol hydrochloride, 60 cases) and study group (treated with Bufei Huoxue capsule combined with ambroxol hydrochloride, 60 cases). Both groups were treated for 3 months. The changes of curative effect, pulmonary function, sleep quality and immune function of the two groups were observed. The adverse reactions of the two groups were observed. Results: The total clinical effective rate in the study group was higher than that in the control group(P<0.05). 3 months after treatment, the first second forced expiratory volume (FEV1), maximum expiratory flow (PEF) and forced vital capacity(FVC) in the study group were higher than those in the control group(P<0.05). 3 months after treatment, the Pittsburgh sleep quality index (PSQI) score in the study group was lower than that in the control group(P<0.05). 3 months after treatment, CD8+ in the study group was lower than that in the control group, and CD3+, CD4+, CD4+/CD8+ were higher than those in the control group (P<0.05). 3 months after treatment, the score of symptoms and signs in study group was lower than that in control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The patients with stable COPD use Bufei Huoxue capsule combined with ambroxol hydrochloride treatment can improve pulmonary function, immune function snd sleep quality, the curative effect is reliable. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |